Biotech Values

[masterlongevity]

gandy wrote the editorial in Lancet that accompanied the bapineuzumab pib-pet paper.

In that editorial, he took much of his editorial space to talk about how dimebon was very promising and going to be a gamechanger in AD. He has been a huge dimebon backer. the fact that he took away from such a significant study to write about dimebon made me lose credibility for him. Whether bapineuzumab ultimatley improves cognition or not, it is the 1st product that has been shown to remove amyloid from the brains of humans.

in his last 3 months in the press, he has written (in order) that
1) bapineuzumab is a game changer
2) dimebon is an even biggger game changer and that what we will see from dimebon will be more important than removing plaque
3) bapineuzumab and all other anti-amloid antibodies has the wrong MOA


to me, he doesn't have much scientific credibility